NR565 Pharmacology Final Exam 2026/2027 | 100+ Questions & Correct Answers | Thyroid, Diabetes, Insulin, Asthma/COPD, GI Drugs, TB, Vaccines & Smoking Cessation

This NR565/NR 565 Pharmacology Final Exam 2026/2027 is a comprehensive 52-page pharmacology exam-preparation resource containing 100+ questions, answers, drug facts, mechanisms of action, adverse effects, contraindications, monitoring requirements, and patient-teaching points. The material concentrates on high-yield pharmacotherapeutic areas including thyroid disorders, diabetes mellitus and insulin therapy, asthma and COPD medications, smoking-cessation pharmacology, tuberculosis treatment, gastrointestinal medications, laxatives, antiemetics, GERD and peptic ulcer disease, IBS pharmacotherapy, and immunizations. The uploaded document specifically identifies itself as a 2026/2027 final-exam resource with “correct answers 100% verified.” A major section covers thyroid pharmacology and endocrine management, beginning with the clinical manifestations of hypothyroidism and hyperthyroidism. The material identifies levothyroxine (Synthroid) as the drug of choice for thyroid hormone replacement and discusses its therapeutic goals, administration on an empty stomach, and TSH monitoring 6–8 weeks after therapy initiation or dosage changes. Hyperthyroidism content reviews Graves disease, toxic nodular goiter, methimazole, propylthiouracil (PTU), beta blockers, and nonradioactive iodine. Important safety topics include methimazole-associated agranulocytosis, first-trimester pregnancy considerations, PTU-associated hepatic toxicity, and the effects of untreated maternal hypothyroidism on fetal and childhood development. The diabetes pharmacology section is especially detailed. It reviews diagnostic thresholds for fasting plasma glucose, random glucose, oral glucose tolerance testing, and HbA1c, along with glycemic goals and monitoring intervals. Insulin material covers total daily dose calculations, basal and bolus replacement, carbohydrate-to-insulin ratios, insulin mixing, and rapid-, short-, intermediate-, long-, and ultralong-acting preparations such as lispro, aspart, regular insulin, NPH, glargine, detemir, and degludec. The document also compares major non-insulin drug classes, including metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, alpha-glucosidase inhibitors, and GLP-1 therapies, emphasizing mechanisms, adverse effects, contraindications, and relative hypoglycemia risk. Another extensive section addresses asthma and COPD pharmacotherapy. Students review stepwise asthma treatment, severity classifications, assessment of impairment and risk, and management of well-controlled, poorly controlled, and very poorly controlled asthma. Medication classes include short-acting and long-acting beta-2 agonists, inhaled and systemic glucocorticoids, leukotriene receptor antagonists, mast-cell stabilizers, methylxanthines, phosphodiesterase-4 inhibitors, and inhaled anticholinergics. Specific drugs include albuterol, salmeterol, beclomethasone, budesonide, fluticasone, prednisone, montelukast, cromolyn, theophylline, roflumilast, ipratropium, and tiotropium. High-yield safety concepts include avoiding LABA monotherapy in asthma, rinsing the mouth after inhaled corticosteroids, the neuropsychiatric warning associated with montelukast, and theophylline toxicity and drug interactions. The resource also provides substantial coverage of smoking-cessation pharmacotherapy and tuberculosis medications. Smoking-cessation material compares bupropion SR, varenicline, nicotine patches, gum, lozenges, nasal spray, and inhalers, including mechanisms, adverse effects, contraindications, duration of treatment, and correct administration. Tuberculosis content reviews isoniazid, rifampin, pyrazinamide, ethambutol, rifapentine, and rifabutin, multidrug treatment principles, prevention after TB exposure, and lifespan considerations involving children, pregnancy, breastfeeding, older adults, and renal function. The gastrointestinal pharmacology material covers proton-pump inhibitors, H2-receptor therapy, constipation medications, antiemetics, antidiarrheals, GERD, peptic ulcer disease, H. pylori eradication, and irritable bowel syndrome pharmacotherapy. Students review omeprazole and CYP450 interactions, long-term PPI-associated nutritional deficiencies, misoprostol pregnancy contraindications, bulk-forming, surfactant, stimulant and osmotic laxatives, and age-specific medication considerations. Antidiarrheal and antiemetic drugs include loperamide, diphenoxylate, bismuth subsalicylate, metoclopramide, ondansetron, promethazine, and prochlorperazine. H. pylori material includes PPI-based triple and quadruple regimens, while IBS pharmacology covers alosetron, eluxadoline, lubiprostone, and linaclotide. The final section focuses on vaccines and immunization pharmacology, including live attenuated vaccines, contraindications in immunocompromised patients, hepatitis B vaccination, rabies post-exposure vaccination, Tdap, expected vaccine reactions, and age-specific immunizations. The document reviews vaccine schedules for 4-month-old, 12-month-old, and 11-year-old patients and identifies examples such as rotavirus, DTaP, Hib, pneumococcal, IPV, hepatitis A and B, MMR, varicella, influenza, HPV, Tdap, and meningococcal vaccines. It concludes with characteristic manifestations of measles, mumps, varicella, rubella, and pertussis. Relevant students: NR565 students, NR 565 students, advanced pharmacology students, Family Nurse Practitioner students, FNP students, Adult-Gerontology Nurse Practitioner students, AGNP students, MSN students, DNP students, APRN students, graduate nursing students, advanced practice nursing students, nurse practitioner pharmacology students, primary care NP students, prescriber pharmacology students, clinical pharmacology exam candidates Source accuracy note: The uploaded document identifies the course as NR565/NR 565 Pharmacology and the academic period as 2026/2027, with publication year 2026. It contains extensive pharmacology questions and answers but does not identify a university or provide a formal APA bibliography, referenced textbook, or journal citation. Therefore, no unsupported university or academic reference has been invented. Keywords: NR565 Pharmacology Final Exam, NR 565 Pharmacology Final Exam, NR565 Final Exam 2026, NR565 Final Exam 2026/2027, NR565 questions and answers, NR565 correct answers, NR565 study guide, NR565 practice exam, advanced pharmacology final exam, nurse practitioner pharmacology, FNP pharmacology, APRN pharmacology, levothyroxine, methimazole, propylthiouracil, hypothyroidism pharmacology, hyperthyroidism pharmacology, diabetes pharmacology, HbA1c, metformin, sulfonylureas, SGLT2 inhibitors, DPP4 inhibitors, GLP1 drugs, insulin therapy, insulin calculations, asthma pharmacology, COPD pharmacology, albuterol, inhaled corticosteroids, montelukast, theophylline, roflumilast, smoking cessation medications, bupropion, varenicline, nicotine replacement therapy, tuberculosis pharmacology, isoniazid, rifampin, gastrointestinal pharmacology, proton pump inhibitors, omeprazole, laxatives, antiemetics, antidiarrheals, H pylori treatment, GERD pharmacology, peptic ulcer disease, IBS medications, vaccine pharmacology, immunization schedule, advanced nursing pharmacology